Form 4: Cortice Biosciences Ceases to be Section 16 Reporting Person for CNS Pharmaceuticals
SEC Form 4 Filing
Cortice Biosciences, Inc. is no longer subject to Section 16 reporting requirements due to an increase in the number of outstanding shares of CNS Pharmaceuticals, Inc.
Summary
- Cortice Biosciences, Inc. has ceased to be a Section 16 reporting person for CNS Pharmaceuticals, Inc.
- This change is due to an increase in the number of outstanding shares of CNS Pharmaceuticals' Common Stock.
- The filing reports Cortice Biosciences' beneficial ownership of 573,368 shares of Common Stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing indicating a change in reporting status. It is neutral in sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC for insiders of publicly traded companies. The cessation of Section 16 reporting obligations for a major shareholder can sometimes signal a change in investment strategy or ownership threshold.
Stakeholder Impact
- Shareholders may be interested in the change in Cortice Biosciences' reporting status, as it could indicate a shift in their investment strategy or ownership level.
Key Dates
| Date | Description |
|---|---|
| 07/30/2024 | Date of earliest transaction |
| 08/06/2024 | Signature date of the Form 4 filing |
Keywords
Section 16, reporting person, CNS Pharmaceuticals, Cortice Biosciences, beneficial ownership, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.